Similar to TACE, even TARE in combination with nivolumab was demonstrated as a safe and effective treatment for HCC patients, showing a higher objective response rate (ORR) compared to both TARE alone and anti-PD-1 agents alone (30.6% vs. 20% vs. 15–23%, respectively) [131]; of note, the ORR in patients without extrahepatic spread was 43.5%, suggesting that TARE followed by nivolumab should be further evaluated in patients with BCLC B or BCLC C with no extrahepatic spread. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.